Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with AzacytidineRoberto Latagliata,Gianluca Cristiano, Dorela Lama,Susanna Fenu,Lorenzo Rizzo,Benedetta Cambo,Simone Zoletto,Francesca Spirito,Fabrizio Cavalca,Daniele Cattaneo,Natalia Cenfra,Giulia De Luca,Beatrice Esposito Vangone,Ambra Di Veroli,Raffaele Palmieri,Mario Annunziata,Olga Mulas,Elisabetta Abruzzese,Alfredo Molteni,Monica Piedimonte,Ida Carmosino,Prassede Salutari,Annalisa Biagi,Monica Bocchia,Michelina Santopietro,Gianni Binotto,Alessandra Iurlo,Monica Crugnola,Marta Riva,Anna Lina Piccioni,Elena Maria Elli,Antonio Curti,Antonella PoloniBlood（2023）Cited 0|Views44No scoreKey wordsNeutropenic PatientsAI Read ScienceMust-Reading TreeExampleGenerate MRT to find the research sequence of this paperChat PaperSummary is being generated by the instructions you defined
